28049-63-0

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-fluorophenyl)cyclobutanecarbonitrile is used as a key building block for the synthesis of various pharmaceuticals. Its ability to undergo nucleophilic aromatic substitution and other reactions makes it a versatile compound in the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 1-(2-fluorophenyl)cyclobutanecarbonitrile is utilized as a starting material for the preparation of different agrochemicals. Its reactivity and structural properties contribute to the creation of compounds that can be used in the development of pesticides, herbicides, and other agricultural products to enhance crop protection and yield.
Used in Academic Research:
1-(2-fluorophenyl)cyclobutanecarbonitrile is employed as a valuable intermediate in academic research, where it is used to explore new reaction pathways and synthesize a wide range of biologically active compounds. Its application in research facilitates the discovery of novel chemical entities with potential applications in various fields, including medicine and agriculture.
Used in Industrial Research:
This chemical compound is also widely used in industrial research, where it serves as a crucial intermediate in the production of advanced materials. Its structural properties and reactivity make it an essential component in the development of new materials with improved properties, such as enhanced stability, reactivity, or selectivity, for various applications in different industries.

Upstream product

• 142-28-9 1,3-Dichloropropane 
• 326-62-5 2-fluorophenyl acetonitrile 
• 109-64-8 1,3-dibromo-propane 

Downstream Products

• 859164-47-9 C-[1-(2-fluoro-phenyl)-cyclobutyl]-methylamine 
• 1358803-14-1 [1-(2-fluorophenyl)cyclobutyl](pyridin-2-yl)methanol 
• 151157-48-1 1-(2-Fluorophenyl)cyclobutanecarboxylic Acid 

Relevant academic research and scientific papers

Synthesis method of arylcyclobutane compound

The present invention discloses a method for synthesizing an arylcyclobutane compound to 1eq phenylacetonitrile and 1.1eq 1-bromo-3-chloropropane as raw material, N,N- dimethylacetamide as a solvent, plus 2.5eq sodium hydride, under the protection of iner

Oxadiazole Amine Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same

The present invention relates to a novel compound having an activity of inhibiting histone deacetylase 6 (HDAC6), an optical isomer thereof or a pharmaceutically acceptable salt thereof, a use thereof for preparation of a drug for treatment, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing the same. The novel compound, an optical isomer thereof or a pharmaceutically acceptable salt thereof according to the present invention has an activity of inhibiting histone deacetylase 6 (HDAC6), and is effective for preventing or treating HDAC6-related diseases, including infectious diseases; neoplasm; endocrine, nutritional and metabolic diseases; mental and behavior disorders; nerve disorders; eye and adnexa diseases; cardiovascular diseases; respiratory diseases; digestive organ diseases; skin and subcutaneous tissue diseases; musculoskeletal and connective tissue diseases; or congenital malformation, deformation and chromosomal abnormality.COPYRIGHT KIPO 2017

NOVEL TRPV3 MODULATORS

Disclosed herein are modulators of TRPV3 of formula (I) wherein G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, u, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

NOVEL TRPV3 MODULATORS

Disclosed herein are modulators of TRPV3 of formula (I), wherein G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, u, and p are as defined in the specifica

CB1 MODULATOR COMPOUNDS

Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.

11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA

Compounds having Formula (I), including pharmaceutically acceptable salts, hydrates and solvates thereof, are selective inhibitors of the 11β-HSD1 enzyme. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dylsipidemia, hyperlipidemia, hypertension, Syndrome X, and other symptoms associated with NIDDM.